Minovés-Kotzki
Welcome,         Profile    Billing    Logout  
 21 Trials 
37 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pépin, Jean-Louis JP
keePaOSA, NCT04875897: Efficacy and Safety of keepMED Positive Airway Pressure Device in Patients With Obstructive Sleep Apnea

Not yet recruiting
N/A
65
NA
keepMED PAP device
keepMED Ltd., CRI-The Clinical Research Institute GmbH
Obstructive Sleep Apnea
01/22
02/22
SLEEPCONNECT, NCT04054180: Multimodal Remote Monitoring and Integrated Educational Program in OSA Patients Initiating Continuous Positive Airway Pressure (CPAP):

Terminated
N/A
41
Europe
CPAP associated with connected devices: blood pressure monitor , scales and activity monitor
University Hospital, Grenoble, SEFAM MEDICAL (Villiers les Nancy, France)
Obstructive Sleep Apnea Syndrome
01/24
02/24
PWV follow-up, NCT04704401: Long-Term Follow-up in Patients Included in the Meta-analysis "Sleep Apnea Syndrome and Arterial Stiffness"

Recruiting
N/A
893
Europe
Questionnaire
University Hospital, Grenoble
Sleep Apnea
10/25
10/25
ESADAfollow-up, NCT04800341: Long-term Follow-up in Patients Included in the European Sleep Apnea Data Base (ESADA)

Recruiting
N/A
500
Europe
Questionnaire
University Hospital, Grenoble
Sleep Apnea
11/25
11/25
NCT05698602: Safety and Performance of NivolisMonitor and NivolisAnton for Monitoring Patients on Ventilatory Assistance at Home

Active, not recruiting
N/A
10
Europe
NivolisMonitor, NivolisAnton
VIVARDIS
Respiratory Insufficiency, Respiratory Failure, Home Monitoring
07/25
12/25
NCT02264431: Severe Obesity Outcome Network Cohort (SOON)

Recruiting
N/A
500
Europe
University Hospital, Grenoble, Act For Chronic Diseases, HP2 laboratory INSERM U1042, University Grenoble Alps
Obesity, Obstructive Sleep Apnea, Sleep
01/24
01/24
WIVOP-Scales, NCT05823025: Withings Study to Analyze the Accuracy of Pulse Wave Velocity Measurement With Bathroom Scales

Not yet recruiting
N/A
176
Europe
PWV measurement
Withings
Vascular Stiffness
05/24
11/24
CARDIATEAM, NCT04303364: CARdiomyopathy in Type 2 DIAbetes Mellitus

Recruiting
N/A
1600
Europe
Institut National de la Santé Et de la Recherche Médicale, France
Cardiomyopathy, Diabetic
10/27
10/27
ASCENT, NCT04399200: Apnea, Stroke and Incident Cardiovascular Events

Recruiting
N/A
1620
Europe
Treatment according to standard care recommandation
University Hospital, Grenoble
Stroke, Sleep-disordered Breathing, Sleep Apnea Syndromes, Sleep Apnea, Obstructive, Sleep Apnea, Central, Fragmentation, Sleep
06/30
06/35
SCOOP-RNPC, NCT05857319: Study Consortium for Evaluation of RNPC Program in Obese and Overweight Patients

Not yet recruiting
N/A
10000
NA
Nutritional Psycho-Behavioral Reeducation Program, RNPC Program
Groupe Éthique et Santé, University Grenoble Alps, Novo Nordisk A/S, Lyon Est University
Overweight and Obesity, Cardiovascular Diseases, Metabolic Disease, Diabete Type 2, Sleep Apnea, Obstructive, NAFLD, NASH
07/30
07/30
DECAENS, Thomas
AB-LATE02, NCT04727307: Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial

Recruiting
2
202
Europe
Atezolizumab (neoadjuvant), Tecentriq, Percutaneous Radiofrequency, Bevacizumab (adjuvant), Avastin 400 mg in 16 ml Injection, Avastin 100 mg in 4 ml Injection, Atezolizumab (adjuvant)
University Hospital, Montpellier
Hepatocellular Carcinoma
01/25
07/27
ROWAN, NCT05063565: TheraSphere With Durvalumab and Tremelimumab for HCC

Recruiting
2
100
Europe, US
TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy
Boston Scientific Corporation, Biocompatibles UK Ltd
Hepatocellular Carcinoma
06/27
06/27
NCT02824185: Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) in Curative Treatment of a Hepatocellular Carcinoma

Completed
N/A
61
Europe
PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)
Hospices Civils de Lyon
Patients Eligible to a Curative Treatment for Primary HCC
01/23
01/23
COVID19-CHIEF, NCT04367805: COVID-19 Infection in Patients With Hepatocellular Carcinoma

Active, not recruiting
N/A
23
Europe
nasopharyngeal Covid 19 RT-PCR
Centre Hospitalier Universitaire, Amiens, Centre Hospitalier-Universitaire Bondy, University Hospital, Bordeaux, Centre Hospitalier-Universitaire CLICHY, Centre Hospitalier Général CORBEIL-ESSONNE, CHU CRETEIL, University Hospital, Grenoble, University Hospital, Lille, CHU LYON, Poitiers University Hospital, Rennes University Hospital, University Hospital, Rouen, University Hospital, Toulouse, CHU VILLEJUIF, Central Hospital, Nancy, France, Centre Hospitalier Universitaire de Nice, University Hospital, Montpellier
Hepatocellular Carcinoma, COVID-19
10/23
10/24
BLANC, Jean-Frédéric
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Active, not recruiting
3
556
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
09/24
10/24
OSCAR, NCT02885753: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

Recruiting
3
348
Europe
Oxaliplatin intravenous, Oxaliplatin IV, 5 FU bolus, 5 FU, Folinic acid, Folinic Acid IV, Oxaliplatin intra-arteriel, Oxaliplatin IA, Panitumumab, Pani, Bevacizumab, Beva, 5 FU continuous, Irinotecan, IRI
Federation Francophone de Cancerologie Digestive
Colorectal Neoplasms
09/25
09/27
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
GEMOXIA-02, NCT03364530: Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

Recruiting
2
40
Europe
Gemcitabine-Oxaliplatin Regimen, Hepatic intra arterial chemotherapy
University Hospital, Montpellier, Federation Francophone de Cancerologie Digestive
Cholangiocarcinoma Non-resectable, Non-metastatic
06/24
06/25
Ta-Len-Tra, NCT05901194: Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma

Not yet recruiting
1/2
25
Europe
Lenvatinib
Assistance Publique - Hôpitaux de Paris, Laboratoire EISAI
Hepatocellular Carcinoma Non-resectable
12/26
07/27
COVID19-CHIEF, NCT04367805: COVID-19 Infection in Patients With Hepatocellular Carcinoma

Active, not recruiting
N/A
23
Europe
nasopharyngeal Covid 19 RT-PCR
Centre Hospitalier Universitaire, Amiens, Centre Hospitalier-Universitaire Bondy, University Hospital, Bordeaux, Centre Hospitalier-Universitaire CLICHY, Centre Hospitalier Général CORBEIL-ESSONNE, CHU CRETEIL, University Hospital, Grenoble, University Hospital, Lille, CHU LYON, Poitiers University Hospital, Rennes University Hospital, University Hospital, Rouen, University Hospital, Toulouse, CHU VILLEJUIF, Central Hospital, Nancy, France, Centre Hospitalier Universitaire de Nice, University Hospital, Montpellier
Hepatocellular Carcinoma, COVID-19
10/23
10/24
LATOURNERIE, Marianne
ProPILARifax, NCT03069131: Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites

Completed
3
160
Europe
Rifaximin, Placebo
Centre Hospitalier Universitaire de Besancon, Alfasigma S.p.A., LC2 PHARMA
Cirrhosis, Ascites, Peritonitis
06/22
03/23
GAVAPROSEC, NCT03705078: "Early TIPS" Versus Glue Obliteration to Prevent Rebleeding From Gastric Varices

Active, not recruiting
N/A
104
Europe
Transjugular Portosytemic Shunt (TIPS), glue obliteration
Centre Hospitalier Universitaire de Besancon
Bleeding Gastric Varices, Cirrhosis
02/23
03/24
CARDIOFIBROCIR, NCT06327308: Evaluation of Cirrhotic Cardiomyopathy by Cardiac MRI in Patients Waiting for Liver Transplant.

Not yet recruiting
N/A
60
Europe
MRI, Blood sampling
Centre Hospitalier Universitaire de Besancon
Cirrhosis
03/25
12/27
REGNAULT, Hélène
FFCD 2101-PRODIGE 81, NCT05665348: Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Not yet recruiting
2/3
574
Europe
Ipilimumab Injection, Atezolizumab, Bevacizumab, Atezolizumab Injection
Federation Francophone de Cancerologie Digestive
HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor
09/24
04/26
TERTIO, NCT05528952: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Recruiting
2
105
Europe
Atezolizumab, Bevacizumab, UCPVax
Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group, PRODIGE
Hepatocellular Carcinoma
04/25
09/27
SIRtain, NCT05967143: Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors ( Registry)

Recruiting
N/A
845
Europe
SIRT
Sirtex Medical
Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
06/28
06/29
BOUATTOUR, Mohamed
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
TERTIO, NCT05528952: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Recruiting
2
105
Europe
Atezolizumab, Bevacizumab, UCPVax
Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group, PRODIGE
Hepatocellular Carcinoma
04/25
09/27
SIROCHO, NCT05265208: Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer

Suspended
2
62
Europe
Capecitabine, L01BC06, Selective Internal Radiotherapy (SIRT), Surgery
Center Eugene Marquis
Resectable Intrahepatic Cholangiocarcinoma
09/27
02/30
NCT05733598: RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Not yet recruiting
2
60
Europe, US
RP3, atezolizumab, bevacizumab
Replimune Inc., Roche Pharma AG
Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
04/27
07/27
HESTIA, NCT05622071: Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions

Recruiting
2
50
Europe
Tislelizumab, BGB-A317
UNICANCER
Hepatocellular Carcinoma by BCLC Stage
11/27
04/28
COVID19-CHIEF, NCT04367805: COVID-19 Infection in Patients With Hepatocellular Carcinoma

Active, not recruiting
N/A
23
Europe
nasopharyngeal Covid 19 RT-PCR
Centre Hospitalier Universitaire, Amiens, Centre Hospitalier-Universitaire Bondy, University Hospital, Bordeaux, Centre Hospitalier-Universitaire CLICHY, Centre Hospitalier Général CORBEIL-ESSONNE, CHU CRETEIL, University Hospital, Grenoble, University Hospital, Lille, CHU LYON, Poitiers University Hospital, Rennes University Hospital, University Hospital, Rouen, University Hospital, Toulouse, CHU VILLEJUIF, Central Hospital, Nancy, France, Centre Hospitalier Universitaire de Nice, University Hospital, Montpellier
Hepatocellular Carcinoma, COVID-19
10/23
10/24
OPERANDI-HCC, NCT06334965: Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

Not yet recruiting
N/A
180
Europe
Simultaneous 18F-Choline PET-MRI
Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma, Radioembolization
11/27
09/29
TARGETMONITO, NCT05443087: TARGETed Therapy Drug MONITOring in DIGestive Oncology

Recruiting
N/A
330
Europe
Blood sampling to build population pharmacokinetics model
UNICANCER
Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST, Neuroendocrine Tumors
08/26
06/27
SIRtain, NCT05967143: Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors ( Registry)

Recruiting
N/A
845
Europe
SIRT
Sirtex Medical
Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
06/28
06/29
SOBESKY, Rodolphe
Quali-SAT, NCT04779593: Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE Haemochromatosis

Recruiting
N/A
240
Europe
Clinical examination, SF36 questionnaire, AIMS2_SF questionnaire, WOMAC questionnaire, EQ-5D-5L questionnaire, Blood Sample Complete blood count, Blood Sample Iron panel, Blood Sample Fasting Glucose, Blood sample lipid panel, Blood sample liver panel, Blood sample C reactive protein, Bloodletting - control group, BioBank, Medico-economical, Bloodletting - experimental group
Rennes University Hospital
Haemochromatosis
01/27
01/27

Download Options